US Supreme Court Lets $655.5 Million Judgment Against Palestinian Authorities Stand During Appeal 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Airbus Joins Air India A320 Altitude Drop Probe 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
US Embassies Urge Americans to Leave Middle East as Iran Tensions Escalate 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak 
FAA Proposes Inspections for Boeing 737 MAX Passenger Seats Over Installation Concern 
AI Data Center Boom Faces New Risks as Public Backlash and Policy Scrutiny Grow 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
ICE to Complete Nationwide Body Camera Rollout by End of August 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
FCC Steps Up China Tech Crackdown as Beijing Pushes Back 
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Trump Administration to Ban Chinese Robots, Power Inverters Over AI Security Concerns 
SEC Clears Path for Data Center Securitizations as AI Financing Demand Surges 
Hims & Hers Health announced on Saturday that it will stop offering access to its compounded semaglutide pill following a warning from the U.S. Food and Drug Administration, which said it would take action against the telehealth company over its $49 weight-loss medication. The decision marks a significant shift for the fast-growing digital health provider as regulatory scrutiny around compounded weight-loss drugs continues to intensify.
The compounded semaglutide pill had been marketed as a more affordable alternative to brand-name GLP-1 weight-loss drugs, which have surged in popularity due to their effectiveness in treating obesity and supporting metabolic health. By offering the pill through its telehealth platform, Hims & Hers aimed to expand access for patients who were unable to obtain or afford FDA-approved injectable versions. However, the FDA has made it clear that compounded versions of semaglutide raise safety and compliance concerns, particularly when they are promoted outside of strict regulatory allowances.
In its statement, Hims & Hers emphasized that patient safety and regulatory compliance remain top priorities. The company said it would work to align its offerings with FDA guidance while continuing to provide other weight-management services and treatments through its platform. This move reflects the growing pressure on telehealth providers to ensure that compounded medications are used only in limited, legally permitted circumstances, such as during officially recognized drug shortages.
The FDA’s stance signals a broader effort to rein in telehealth companies that have rapidly entered the weight-loss market by offering lower-cost alternatives to popular obesity drugs. As demand for semaglutide-based treatments remains strong, regulators are increasingly focused on preventing the widespread distribution of compounded versions that may not meet the same safety and quality standards as approved medications.
For consumers, the development underscores the importance of understanding the differences between FDA-approved drugs and compounded alternatives. As Hims & Hers adjusts its strategy, the company is expected to continue exploring compliant ways to meet demand for weight-loss solutions while navigating an evolving regulatory landscape that is reshaping the future of telehealth and obesity treatment.
